SFXN2: A Potential Drug Target and Biomarker for the Treatment of Sleep-Disordered Breathing

Target Name: SFXN2

NCBI ID: G118980

SFXN2

SFXN2: A Potential Drug Target and Biomarker for the Treatment of Sleep-Disordered Breathing

Sleep-disordered breathing, also known as sleep apnea, is a common condition that affects millions of people worldwide. It occurs when the airflow to the body is repeatedly blocked or restricted during sleep, leading to periods of disrupted sleep and potentially serious health consequences. According to the American Sleep Foundation, approximately 26 million Americans have sleep apnea, and it is estimated that over 1 million of them have the condition that requires treatment.

One potential drug target for the treatment of sleep-disordered breathing is SFXN2, a protein that is expressed in the brains of people with sleep-disordered breathing. SFXN2 has been shown to play a role in the regulation of sleep-wake cycles and has been linked to the development of sleep-disordered breathing.

SFXN2 is a homeobox gene that is expressed in the brain and other tissues. It is involved in the development and maintenance of neural stem cells and has been shown to play a role in the development of various neurological and psychiatric disorders, including sleep-disordered breathing.

SFXN2 has been shown to regulate the expression of genes that are involved in the development of resistance to the effects of hypoxia, or lack of oxygen, which is a common complication in sleep-disordered breathing. This means that when people with sleep-disordered breathing are exposed to hypoxic stress, SFXN2 has been shown to promote the expression of genes that help to protect against the harmful effects of hypoxia.

In addition, SFXN2 has also been shown to regulate the expression of genes involved in the regulation of sleep-wake cycles. This means that it plays a role in the regulation of the number of wakefulness periods and the length of sleep periods that people have each night.

Furthermore, SFXN2 has also been shown to play a role in the regulation of brain chemistry, including the levels of neurotransmitters such as dopamine and GABA. These neurotransmitters are involved in the regulation of mood, arousal, and sleep-wake cycles, and have been implicated in the development of various psychiatric and neurological disorders.

SFXN2 has also been shown to play a role in the regulation of the immune system, which is involved in the rejection of foreign substances that can cause inflammation and damage in the body. This means that SFXN2 may be involved in the development of sleep-disordered breathing in people with certain genetic variations in the immune system.

In conclusion, SFXN2 is a potential drug target for the treatment of sleep-disordered breathing. Its role in the regulation of sleep-wake cycles, its regulation of brain chemistry, and its involvement in the regulation of the immune system suggest that it may be a valuable target for the development of new treatments for this debilitating and potentially life-threatening condition. Further research is needed to confirm its potential and to develop safe and effective treatments.

Protein Name: Sideroflexin 2

Functions: Mitochondrial amino-acid transporter that mediates transport of serine into mitochondria (PubMed:30442778). Involved in mitochondrial iron homeostasis by regulating heme biosynthesis (PubMed:30570704)

The "SFXN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SFXN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets